Real World Insights

Providing Pharma & Biopharma with RWD & AI-Driven Insights on Patient Populations Affected by Speciality & Rare Diseases

Using ML/AI to Find the Right Patients at the Right Time: A Conversation with AVEO Oncology

By: John Seaner, CMO, IPM.ai/Swoop

Ganesh Rajaratnam, Senior Director of Commercial Operations,...

IPM.ai Recognized as One of the World’s Most Innovative Companies in 2022 by Fast Company

IPM.ai’s transformative approach to patient-finding for specialty and rare conditions captures the...

Ron Elwell, CEO and Founder of IPM.ai Wins MM+M’s Pinnacle Award

By: John Seaner, CMO, IPM.ai/Swoop

Ron Elwell, CEO and founder of IPM.ai is a proud recipient of ...

Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle

By: John Seaner, CMO, IPM.ai/Swoop

Life sciences and healthcare companies that set out to pioneer...

Building a Rare Disease Franchise with Machine Learning and Artificial Intelligence

By: John Seaner, CMO, IPM.ai/Swoop

Nitin Choudhary, Managing Principal of IPM.ai and Richard...

A New Reference Model for Clinical Study Recruitment

By: John Seaner, CMO, IPM.ai/Swoop

Conventional clinical study recruitment methods for rare...

Real Chemistry's IPM.ai Expands Partnership with Datavant

San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and...

IPM.ai's Clinical Trial Recruitment Solution Featured in MM&M

By: John Seaner, CMO, IPM.ai/Swoop

Allison Rhee of MM&M reports on IPM.ai's answer to patient...

Kyowa Kirin Uses AI/ML to Uncover Undiagnosed Patients

By: John Seaner, CMO, IPM.ai/Swoop

The rare disease patient journey can be arduous. Many patients...

IPM.ai Accelerates the Clinical Study and Commercialization of Precision Medicine

Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by...